ArticleThe journal of pathology. Clinical research2024

Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.

Michael Menzel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.